Meanwhile, semaglutide, a GLP-1 receptor agonist, has demonstrated weight reduction and glycemic control benefits in KTRs with diabetes or metabolic syndrome, with no significant adverse impact on graft function in small studies. Here, GLP1R is linked to metabolic syndrome.